Drugs / TSN084
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06386705 | Jul 2022 → Dec 2025 overdue | cancer | Tyligand Bioscience (Shanghai) Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT05300438 | Feb 2022 → Mar 2025 | cancer | Tyligand Bioscience (Shanghai) Limited | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSN084 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05300438 ↗ |
| Action | Inhibit | “TSN084 is a novel type II protein kinase inhibitor” NCT05300438 ↗ |
| Modality | Small molecule | “TSN084 is a novel type II kinase inhibitor” NCT06386705 ↗ |
| Route | Oral | “Oral tablets” NCT05300438 ↗ |
| Target | FLT3 | “targets multiple tyrosine kinases, such as c-MET, FLT3” NCT05300438 ↗ |
| Target | MET | “targets multiple tyrosine kinases, such as c-MET” NCT05300438 ↗ |